Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 Open-Label Study of Baricitinib in Japanese Patients with NNS/CANDLE, SAVI, and AGS
jRCT2031200152Phase 3Suspended
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of baricitinib in Nakajo-Nishimura syndrome (NNS), STING-associated vasculopathy with onset in infancy (SAVI) and Aicardi-Goutières syndrome (AGS), sponsored by Eli Lilly and Company. Primary endpoint: Change from Baseline in Mean Daily Diary Scores. Started Oct 2020; status: suspended.
02
Drugs
baricitinib
03
Conditions
Nakajo-Nishimura syndrome (NNS)STING-associated vasculopathy with onset in infancy (SAVI)Aicardi-Goutières syndrome (AGS)
Beyond the preview
Go deeper on jRCT2031200152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200152.